title: Surgery for gastric cancer: what the trials indicate.
abstract: To optimize the therapeutic value of an operation for cancer, surgeons must weigh survival value against mortality/morbidity risk. As a result of several prospective, randomized trials, many surgeons feel that international opinion has reached a consensus. Reflexively radical surgical hubris has certainly given way to a more nuanced, customized approach to this disease. But issues remain. This article critically reviews existing data and emphasizes areas of continued controversy.
authors.affiliation: Department of Surgery, U.C. Davis, VA Northern California Health Care System, Sacramento VA at Mather 10535, Hospital Way (112), Mather, CA 95655-1200, USA. shundahl@comcast.net; scott.hundahl@va.gov
authors.forename: Scott A
authors.initials: SA
authors.lastname: Hundahl
mesh_terms: D001208:Asia; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005060:Europe; D005544:Forecasting; D005743:Gastrectomy / Q000379:methods*; D005773:Gastroscopy / Q000379:methods; D006801:Humans; D015994:Incidence; D010535:Laparoscopy / Q000379:methods; D008197:Lymph Node Excision / Q000379:methods; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging / Q000379:methods; D013019:South Africa; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D014481:United States